CI Bio-Revolution Index ETFTSX:CDNA
- LAST PRICE15.88
- TODAY'S CHANGE (%)0.00 (0.00%)
- Bid / Lots15.73/ 1
- Ask / Lots16.08/ 1
- Open / Previous Close--- / 15.88
- Day Range---
- 52 Week Range
- Volume---
- Overall Morningstar RatingNot Ratedout of funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| US Equity | 81.2% |
|---|---|
| Int'l Equity | 21.9% |
| CDN Equity | 0 |
| Fixed Income | 0 |
| Other | 0 |
| Cash | -3.1% |
| Healthcare | 103.1% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 78.8% |
|---|---|
| Europe | 5.5% |
| Asia/Oceania | 2.4% |
| Africa | 0 |
| Latin America | 0 |
| Canada | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
BioNTech SE ADR | Long | 3.7% | -0.29% | $218.7K |
Bristol-Myers Squibb Co | Long | 3.7% | -0.25% | $215.9K |
Illumina Inc | Long | 3.5% | -0.29% | $205.7K |
AbbVie Inc | Long | 3.2% | -0.30% | $191.3K |
Vertex Pharmaceuticals Inc | Long | 3.1% | -0.36% | $184.5K |
Exact Sciences Corp | Long | 2.9% | -0.28% | $171.2K |
Novartis AG Registered Shares | Long | 2.8% | -0.19% | $162.1K |
Lonza Group Ltd | Long | 2.6% | -0.55% | $154.5K |
Pfizer Inc | Long | 2.5% | -0.26% | $149.6K |
CRISPR Therapeutics AG | Long | 2.5% | -0.26% | $148.5K |
Reports
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | --- |
|---|---|
Category | Sector Equity |
Sponsor | CI Global Asset Management |
Inception | February 24, 2022 |
CDNA seeks to replicate, to the extent reasonably possible, the performance of a global biotechnology and genomics industry index, net of expenses. Currently, CDNA seeks to replicate the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR (the “Indexâ€). The Index intends to track the performance of companies that have business operations in the global biotechnology and genomics industry using the ARTIS® classification system. The Index hedges foreign currency exposure back to Canadian dollars.
| Total Net Assets | $5.9M |
|---|---|
| Shares Out. | 350.0K |
| Net Asset Value (NAV) | $15.86 |
| Prem/Discount to NAV | 10.55% |
| P/E Ratio | --- |
| Dividend Yield | 0.62% |
| Dividend per Share | 0.10 CAD |
| Ex-Dividend Date | 09/23/2024 |
| Dividend Payment Date | 09/27/2024 |
| Beta | --- |
| Morningstar Investment Style | Sector Equity |
| Equity Style | Mid Cap Blend |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.40% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.44% |